3//SEC Filing
Novartis Bioventures Ltd 3
Accession 0000899243-20-017188
CIK 0001538927other
Filed
Jun 17, 8:00 PM ET
Accepted
Jun 18, 9:16 PM ET
Size
12.5 KB
Accession
0000899243-20-017188
Insider Transaction Report
Form 3
NOVARTIS AG
10% Owner
Holdings
- (indirect: See footnote)
Series B Convertible Preferred Stock
→ Common Stock (1,363,723 underlying) - (indirect: See footnote)
Series A Convertible Preferred Stock
→ Common Stock (553,656 underlying) - 331,221(indirect: See footnote)
Common Stock
- (indirect: See footnote)
Series C Convertible Preferred Stock
→ Common Stock (743,105 underlying)
Novartis Bioventures Ltd
10% Owner
Holdings
- 331,221(indirect: See footnote)
Common Stock
- (indirect: See footnote)
Series A Convertible Preferred Stock
→ Common Stock (553,656 underlying) - (indirect: See footnote)
Series C Convertible Preferred Stock
→ Common Stock (743,105 underlying) - (indirect: See footnote)
Series B Convertible Preferred Stock
→ Common Stock (1,363,723 underlying)
Footnotes (2)
- [F1]Novartis Bioventures Ltd. is the record holder of the securities reported herein. As the indirect parent of Novartis Bioventures Ltd., Novartis AG may be deemed to share beneficial ownership of these securities.
- [F2]Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock is convertible into common stock on a one-for-4.2775 basis into the number of share of common stock shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock have no expiration date.
Issuer
Forma Therapeutics Holdings, Inc.,
CIK 0001538927
Entity typeother
IncorporatedBermuda
Related Parties
1- filerCIK 0001297709
Filing Metadata
- Form type
- 3
- Filed
- Jun 17, 8:00 PM ET
- Accepted
- Jun 18, 9:16 PM ET
- Size
- 12.5 KB